drugset / Trial / NCT06037655
Chemotherapy Combined With Adebrelimab and Mecapegfilgrastim in Neoadjuvant Treatment of Potentially Resectable BTC
Phase 2
Not yet recruiting
30 enrolled
The First Affiliated Hospital with Nanjing Medical University
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the safety and efficacy of Gemcitabine/cisplatin combined with Adebrelimab and Mecapegfilgrastim in neoadjuvant treatment of potentially resectable Biliary Tract Neoplasms.
Timeline
- Start
- 2023-09-25
- Primary completion
- 2026-03-31
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | Adebrelimab | Monoclonal antibody | 1200 mg | Intravenous |
| Background | Cisplatin | Other / unclassified | 25 mg/m2 | Intravenous |
| Background | Gemcitabine | Small molecule | 1000 mg/m2 | Intravenous |
| Background | Mecapegfilgrastim | Protein / enzyme biologic | 6 mg | Intravenous |